Marker Therapeutics treats first lymphoma patient in Phase 1 APOLLO trial of MT-601

Marker Therapeutics, Inc.

First patient dosed at 200 million cells; no treatment-related adverse events after 18 days.
Trial enrolls up to 30 patients across 8 U.S. sites for lymphoma patients relapsed after or ineligible for anti-CD19 CAR T therapy.
MT-601 targets six tumor antigens; prior TACTAL study showed durable responses with a five-antigen product.
Nonclinical data from May 2023 showed MT-601 inhibited lymphoma cells regardless of CD19 expression and overcame CAR T resistance.

This headline and bullets were generated automatically by deepseek-v4-flash:cloud@v2 from the public filing. Read the source on SEC.gov before relying on any specific claim. Not investment advice. See methodology for how this pipeline works.